Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) Stock Competitors & Peer Comparison
See SHPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SHPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SHPH | $3.98 | -0.87% | 2.4M | -0.19 | -$21.54 | N/A |
| TAK | $18.52 | -1.83% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $39.90 | +1.81% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.01 | -2.75% | 40.4B | 18.78 | $0.49 | +2.16% |
| ZTS | $70.47 | -0.82% | 29.9B | 10.85 | $6.58 | +2.93% |
| VTRS | $17.91 | +0.45% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.42 | +0.49% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.89 | +5.18% | 10.4B | 20.52 | $0.61 | +0.66% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
SHPH vs TAK Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TAK trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TAK's P/E ratio is 13.59. In terms of profitability, SHPH's ROE is -1.57%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SHPH is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
SHPH vs TEVA Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TEVA trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TEVA's P/E ratio is 13.27. In terms of profitability, SHPH's ROE is -1.57%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, SHPH is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check TEVA's competition here
Haleon plc (NYSE: HLN)
SHPH vs HLN Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while HLN trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas HLN's P/E ratio is 18.78. In terms of profitability, SHPH's ROE is -1.57%, compared to HLN's ROE of +0.17%. Regarding short-term risk, SHPH is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
SHPH vs ZTS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ZTS has a market cap of 29.9B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ZTS trades at $70.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ZTS's P/E ratio is 10.85. In terms of profitability, SHPH's ROE is -1.57%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, SHPH is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
SHPH vs VTRS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while VTRS trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas VTRS's P/E ratio is 7.25. In terms of profitability, SHPH's ROE is -1.57%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, SHPH is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
SHPH vs ITCI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SHPH's ROE is -1.57%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, SHPH is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
SHPH vs CTLT Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SHPH's ROE is -1.57%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SHPH is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
SHPH vs ELAN Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ELAN trades at $22.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ELAN's P/E ratio is 21.17. In terms of profitability, SHPH's ROE is -1.57%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, SHPH is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
SHPH vs RDY Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while RDY trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas RDY's P/E ratio is 20.52. In terms of profitability, SHPH's ROE is -1.57%, compared to RDY's ROE of +0.09%. Regarding short-term risk, SHPH is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
SHPH vs ALKS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ALKS trades at $40.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ALKS's P/E ratio is 42.26. In terms of profitability, SHPH's ROE is -1.57%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SHPH is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
SHPH vs AMRX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while AMRX trades at $20.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas AMRX's P/E ratio is 22.78. In terms of profitability, SHPH's ROE is -1.57%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, SHPH is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
SHPH vs LNTH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while LNTH trades at $99.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas LNTH's P/E ratio is 16.76. In terms of profitability, SHPH's ROE is -1.57%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, SHPH is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
SHPH vs INDV Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while INDV trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas INDV's P/E ratio is 10.10. In terms of profitability, SHPH's ROE is -1.57%, compared to INDV's ROE of -2.16%. Regarding short-term risk, SHPH is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
SHPH vs ALVOW Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ALVOW has a market cap of 3.5B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ALVOW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ALVOW's P/E ratio is 55.38. In terms of profitability, SHPH's ROE is -1.57%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, SHPH is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
SHPH vs RGC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while RGC trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas RGC's P/E ratio is -436.62. In terms of profitability, SHPH's ROE is -1.57%, compared to RGC's ROE of -2.32%. Regarding short-term risk, SHPH is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
SHPH vs SUPN Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while SUPN trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas SUPN's P/E ratio is 14.58. In terms of profitability, SHPH's ROE is -1.57%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, SHPH is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
SHPH vs HCM Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while HCM trades at $14.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas HCM's P/E ratio is 5.30. In terms of profitability, SHPH's ROE is -1.57%, compared to HCM's ROE of +0.01%. Regarding short-term risk, SHPH is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
SHPH vs DCPH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SHPH's ROE is -1.57%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SHPH is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
SHPH vs BHC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while BHC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas BHC's P/E ratio is 1.47. In terms of profitability, SHPH's ROE is -1.57%, compared to BHC's ROE of +0.89%. Regarding short-term risk, SHPH is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
SHPH vs AVDL Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SHPH's ROE is -1.57%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, SHPH is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
SHPH vs TRLV Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TRLV trades at $12.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TRLV's P/E ratio is -5.02. In terms of profitability, SHPH's ROE is -1.57%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, SHPH is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
SHPH vs PRGO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PRGO trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PRGO's P/E ratio is 6.03. In terms of profitability, SHPH's ROE is -1.57%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, SHPH is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
SHPH vs ALVO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ALVO trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ALVO's P/E ratio is -10.42. In terms of profitability, SHPH's ROE is -1.57%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, SHPH is similarly volatile compared to ALVO. This indicates similar risk in terms of short-term price fluctuations for SHPH.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
SHPH vs EMBCV Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SHPH's ROE is -1.57%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, SHPH is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
SHPH vs DVAX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SHPH's ROE is -1.57%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, SHPH is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
SHPH vs ANIP Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ANIP trades at $72.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ANIP's P/E ratio is 9.10. In terms of profitability, SHPH's ROE is -1.57%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, SHPH is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
SHPH vs ETON Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ETON trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ETON's P/E ratio is 155.74. In terms of profitability, SHPH's ROE is -1.57%, compared to ETON's ROE of +0.40%. Regarding short-term risk, SHPH is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
SHPH vs TARO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TARO's P/E ratio is 30.05. In terms of profitability, SHPH's ROE is -1.57%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SHPH is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
SHPH vs PAHC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PAHC trades at $35.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PAHC's P/E ratio is 12.18. In terms of profitability, SHPH's ROE is -1.57%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, SHPH is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
SHPH vs CRON Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CRON trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CRON's P/E ratio is 17.46. In terms of profitability, SHPH's ROE is -1.57%, compared to CRON's ROE of +0.06%. Regarding short-term risk, SHPH is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
SHPH vs AMPH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while AMPH trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas AMPH's P/E ratio is 9.35. In terms of profitability, SHPH's ROE is -1.57%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, SHPH is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
SHPH vs HROW Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while HROW trades at $31.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas HROW's P/E ratio is -31.92. In terms of profitability, SHPH's ROE is -1.57%, compared to HROW's ROE of -1.04%. Regarding short-term risk, SHPH is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
SHPH vs PCRX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PCRX trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PCRX's P/E ratio is 9.77. In terms of profitability, SHPH's ROE is -1.57%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, SHPH is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
SHPH vs PETQ Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SHPH's ROE is -1.57%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SHPH is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
SHPH vs COLL Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, COLL has a market cap of 734M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while COLL trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas COLL's P/E ratio is 2.84. In terms of profitability, SHPH's ROE is -1.57%, compared to COLL's ROE of +0.16%. Regarding short-term risk, SHPH is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
SHPH vs IRWD Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while IRWD trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas IRWD's P/E ratio is 5.28. In terms of profitability, SHPH's ROE is -1.57%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, SHPH is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
SHPH vs AQST Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, AQST has a market cap of 596M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while AQST trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas AQST's P/E ratio is -7.31. In terms of profitability, SHPH's ROE is -1.57%, compared to AQST's ROE of +2.44%. Regarding short-term risk, SHPH is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
SHPH vs BDSI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SHPH's ROE is -1.57%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SHPH is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
SHPH vs EVO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, EVO has a market cap of 564.8M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while EVO trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas EVO's P/E ratio is -2.25. In terms of profitability, SHPH's ROE is -1.57%, compared to EVO's ROE of -0.27%. Regarding short-term risk, SHPH is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
SHPH vs GLAS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while GLAS trades at $6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas GLAS's P/E ratio is -12.22. In terms of profitability, SHPH's ROE is -1.57%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, SHPH is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
SHPH vs EOLS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while EOLS trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas EOLS's P/E ratio is -25.21. In terms of profitability, SHPH's ROE is -1.57%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, SHPH is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
SHPH vs KMDA Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while KMDA trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas KMDA's P/E ratio is 22.68. In terms of profitability, SHPH's ROE is -1.57%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SHPH is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
SHPH vs TKNO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TKNO trades at $9.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TKNO's P/E ratio is -29.68. In terms of profitability, SHPH's ROE is -1.57%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, SHPH is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
SHPH vs TLRY Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TLRY trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TLRY's P/E ratio is -3.71. In terms of profitability, SHPH's ROE is -1.57%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, SHPH is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
SHPH vs CGC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CGC's P/E ratio is -2.07. In terms of profitability, SHPH's ROE is -1.57%, compared to CGC's ROE of -0.33%. Regarding short-term risk, SHPH is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
SHPH vs EBS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, EBS has a market cap of 354M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while EBS trades at $6.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas EBS's P/E ratio is 4.76. In terms of profitability, SHPH's ROE is -1.57%, compared to EBS's ROE of -0.36%. Regarding short-term risk, SHPH is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
SHPH vs ALIM Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SHPH's ROE is -1.57%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SHPH is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
SHPH vs LNDC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SHPH's ROE is -1.57%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, SHPH is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
SHPH vs ACB Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ACB trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ACB's P/E ratio is -2.95. In terms of profitability, SHPH's ROE is -1.57%, compared to ACB's ROE of -0.21%. Regarding short-term risk, SHPH is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
SHPH vs SIGA Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while SIGA trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas SIGA's P/E ratio is 12.81. In terms of profitability, SHPH's ROE is -1.57%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, SHPH is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SHPH vs LFCR Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while LFCR trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas LFCR's P/E ratio is -5.13. In terms of profitability, SHPH's ROE is -1.57%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, SHPH is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
SHPH vs TYHT Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SHPH's ROE is -1.57%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, SHPH is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
SHPH vs CRDL Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CRDL's P/E ratio is -6.73. In terms of profitability, SHPH's ROE is -1.57%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, SHPH is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
SHPH vs ORGO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ORGO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ORGO's P/E ratio is 46.00. In terms of profitability, SHPH's ROE is -1.57%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, SHPH is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
SHPH vs REPH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas REPH's P/E ratio is -8.04. In terms of profitability, SHPH's ROE is -1.57%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SHPH is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
SHPH vs DERM Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while DERM trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas DERM's P/E ratio is -29.23. In terms of profitability, SHPH's ROE is -1.57%, compared to DERM's ROE of -0.20%. Regarding short-term risk, SHPH is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
SHPH vs THTX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas THTX's P/E ratio is -28.83. In terms of profitability, SHPH's ROE is -1.57%, compared to THTX's ROE of +0.36%. Regarding short-term risk, SHPH is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
SHPH vs OGI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while OGI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas OGI's P/E ratio is 2.44. In terms of profitability, SHPH's ROE is -1.57%, compared to OGI's ROE of +0.21%. Regarding short-term risk, SHPH is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
SHPH vs ASRT Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ASRT's P/E ratio is -7.10. In terms of profitability, SHPH's ROE is -1.57%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, SHPH is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
SHPH vs SCTL Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SHPH's ROE is -1.57%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SHPH is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
SHPH vs CPIX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CPIX trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CPIX's P/E ratio is -19.30. In terms of profitability, SHPH's ROE is -1.57%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, SHPH is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
SHPH vs PROC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PROC's P/E ratio is 1.53. In terms of profitability, SHPH's ROE is -1.57%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SHPH is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
SHPH vs OPTN Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SHPH's ROE is -1.57%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, SHPH is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
SHPH vs ZOM Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SHPH's ROE is -1.57%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, SHPH is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
SHPH vs GRVI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SHPH's ROE is -1.57%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, SHPH is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
SHPH vs BGM Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while BGM trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas BGM's P/E ratio is -1.46. In terms of profitability, SHPH's ROE is -1.57%, compared to BGM's ROE of -0.05%. Regarding short-term risk, SHPH is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
SHPH vs ZYNE Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SHPH's ROE is -1.57%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SHPH is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
SHPH vs SSIC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas SSIC's P/E ratio is 11.93. In terms of profitability, SHPH's ROE is -1.57%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, SHPH is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
SHPH vs TLPH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TLPH trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TLPH's P/E ratio is -3.84. In terms of profitability, SHPH's ROE is -1.57%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, SHPH is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
SHPH vs ZYBT Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ZYBT trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, SHPH's ROE is -1.57%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, SHPH is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
SHPH vs VLNS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SHPH's ROE is -1.57%, compared to VLNS's ROE of N/A. Regarding short-term risk, SHPH is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
SHPH vs INCR Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while INCR trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas INCR's P/E ratio is -4.92. In terms of profitability, SHPH's ROE is -1.57%, compared to INCR's ROE of -0.09%. Regarding short-term risk, SHPH is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
SHPH vs DRRX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SHPH's ROE is -1.57%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, SHPH is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
SHPH vs JUPW Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SHPH's ROE is -1.57%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, SHPH is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
SHPH vs QLI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas QLI's P/E ratio is -4.92. In terms of profitability, SHPH's ROE is -1.57%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SHPH is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
SHPH vs RMTI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while RMTI trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas RMTI's P/E ratio is -6.44. In terms of profitability, SHPH's ROE is -1.57%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, SHPH is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
SHPH vs HEXO Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SHPH's ROE is -1.57%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SHPH is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
SHPH vs CPHI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CPHI trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CPHI's P/E ratio is -1.69. In terms of profitability, SHPH's ROE is -1.57%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, SHPH is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
SHPH vs TXMD Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, TXMD has a market cap of 24.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while TXMD trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas TXMD's P/E ratio is 106.47. In terms of profitability, SHPH's ROE is -1.57%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, SHPH is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
SHPH vs CYTH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SHPH's ROE is -1.57%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SHPH is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
SHPH vs AYTU Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while AYTU trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas AYTU's P/E ratio is -0.47. In terms of profitability, SHPH's ROE is -1.57%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, SHPH is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
SHPH vs EVOK Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SHPH's ROE is -1.57%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, SHPH is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
SHPH vs OPTH Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while OPTH trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas OPTH's P/E ratio is -3.37. In terms of profitability, SHPH's ROE is -1.57%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, SHPH is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
SHPH vs ACRX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SHPH's ROE is -1.57%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, SHPH is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
SHPH vs CABR Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while CABR trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas CABR's P/E ratio is -1.59. In terms of profitability, SHPH's ROE is -1.57%, compared to CABR's ROE of -3.86%. Regarding short-term risk, SHPH is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
SHPH vs AGRX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SHPH's ROE is -1.57%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SHPH is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
SHPH vs NLTX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SHPH's ROE is -1.57%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, SHPH is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
SHPH vs LCI Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas LCI's P/E ratio is -0.04. In terms of profitability, SHPH's ROE is -1.57%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SHPH is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
SHPH vs ADMP Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SHPH's ROE is -1.57%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SHPH is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
SHPH vs GELS Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while GELS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas GELS's P/E ratio is -1.09. In terms of profitability, SHPH's ROE is -1.57%, compared to GELS's ROE of -0.25%. Regarding short-term risk, SHPH is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
SHPH vs YCBD Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while YCBD trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas YCBD's P/E ratio is -1.14. In terms of profitability, SHPH's ROE is -1.57%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, SHPH is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
SHPH vs MNK Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas MNK's P/E ratio is -0.44. In terms of profitability, SHPH's ROE is -1.57%, compared to MNK's ROE of -0.36%. Regarding short-term risk, SHPH is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
SHPH vs FLGC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SHPH's ROE is -1.57%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, SHPH is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
SHPH vs UPC Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while UPC trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas UPC's P/E ratio is -0.61. In terms of profitability, SHPH's ROE is -1.57%, compared to UPC's ROE of -0.03%. Regarding short-term risk, SHPH is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
SHPH vs PLXP Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PLXP's P/E ratio is -0.22. In terms of profitability, SHPH's ROE is -1.57%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, SHPH is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
SHPH vs INM Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while INM trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas INM's P/E ratio is -0.25. In terms of profitability, SHPH's ROE is -1.57%, compared to INM's ROE of -1.35%. Regarding short-term risk, SHPH is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for SHPH.Check INM's competition here
Athenex, Inc. (NASDAQ: ATNX)
SHPH vs ATNX Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas ATNX's P/E ratio is -0.02. In terms of profitability, SHPH's ROE is -1.57%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, SHPH is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
SHPH vs SNOA Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while SNOA trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas SNOA's P/E ratio is -1.14. In terms of profitability, SHPH's ROE is -1.57%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, SHPH is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
SHPH vs PROCW Comparison September 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SHPH stands at 2.4M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, SHPH is priced at $3.98 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SHPH currently has a P/E ratio of -0.19, whereas PROCW's P/E ratio is N/A. In terms of profitability, SHPH's ROE is -1.57%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, SHPH is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for SHPH.Check PROCW's competition here